Freeform Search

Database	US Pre-Grant Publication Full-Text Database US Patents Full-Text Database US OCR Full-Text Database EPO Abstracts Database JPO Abstracts Database Derwent World Patents Index IBM Technical Disclosure Bulletins				
Term:	L19 and krieg	Approximately and the second s			
Display:	Documents in Display Format: -	Starting with Number 1			
Generate	O Hit List • Hit Count O Side by Side O	Image			
Search Clear Interrupt					
Search History					

DATE: Monday, October 18, 2004 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=PGP	B, USPT, USOC,EPAB,JPAB,DWPI; PLUR=YE	S; OP=ADJ	
<u>L20</u>	L19 and krieg	143	<u>L20</u>
<u>L19</u>	L18 and 115	610	<u>L19</u>
<u>L18</u>	17 and 114	799	<u>L18</u>
<u>L17</u>	L16 same 114	13	<u>L17</u>
<u>L16</u>	L15 with 19	4340	<u>L16</u>
<u>L15</u>	antigen	124937	<u>L15</u>
<u>L14</u>	cpg with oligonucleotide	2011	<u>L14</u>
<u>L13</u>	cpg with oligonucleoitide	0	<u>L13</u>
<u>L12</u>	19 and 16	53	<u>L12</u>
<u>L11</u>	19 same 16	12	<u>L11</u>
<u>L10</u>	L9 same 18	4	<u>L10</u>
<u>L9</u>	exposed	1340699	<u>L9</u>
<u>L8</u>	L7 same 16	22	<u>L8</u>
<u>L7</u>	mucosal or intran\$	79245	<u>L7</u>
<u>L6</u>	cpg with oligonucleotide with antigen	122	<u>L6</u>
<u>L5</u>	cpg with intranasal	15	<u>L5</u>

<u>L4</u>	cpg with mucosal	47	<u>L4</u>
<u>L3</u>	mucosal and 12	1	<u>L3</u>
<u>L2</u>	6218371.pn.	2	<u>L2</u>
<u>L1</u>	6218791.pn.	2	<u>L1</u>

END OF SEARCH HISTORY

Previous Doc Next Doc Go to Doc# First Hit Fwd Refs

Generate Collection

L4: Entry 41 of 47

File: USPT

Jun 18, 2002

US-PAT-NO: 6406705

DOCUMENT-IDENTIFIER: US 6406705 B1

TITLE: Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant

DATE-ISSUED: June 18, 2002

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Davis; Heather L. Ottawa CA

Schorr; Joachim Hilden DE

Krieg; Arthur M. Iowa City IA

 $\text{US-CL-CURRENT: } \underline{424/278.1}; \ \underline{424/204.1}, \ \underline{424/279.1}, \ \underline{424/282.1}, \ \underline{536/23.72}, \ \underline{930/200},$

930/210, 930/220

CLAIMS:

We claim:

1. A composition of a synergistic combination of adjuvants, comprising:

an effective amount for inducing a synergistic adjuvant response of a combination of adjuvants, wherein the combination of adjuvants includes at least one oligonucleotide containing at least one unmethylated CpG dinucleotide and at least one non-nucleic acid adjuvant.

- 2. The composition of claim 1, wherein the non-nucleic acid is an adjuvant that creates a depo effect.
- 3. The composition of claim 2, wherein the adjuvant that creates a depo effect is selected from the group consisting of alum, emulsion based formulations, mineral oil, non-mineral oil, water-in-oil emulsions, water-in-oil-in-water emulsions, Seppic ISA series of Montanide adjuvants; MF-59; and PROVAX.
- 4. The composition of claim 1, wherein the non-nucleic acid adjuvant is an immune stimulating adjuvant.
- 5. The composition of claim 4, wherein the immune stimulating adjuvant is selected from the group consisting of saponins, PCPP polymer; derivatives of lipopolysaccharides, MPL, MDP, t-MDP, OM-174 and Leishmania elongation factor.
- 6. The composition of claim 1, wherein the non-nucleic acid adjuvant is an adjuvant that creates a depo effect and stimulates the immune system.
- 7. The composition of claim 6, wherein the adjuvant that creates a depo effect

- and stimulates the immune system is selected from the group consisting of ISCOMS, SB-AS2, AS2, SB-AS4, non-ionic block copolymers and SAF.
- 8. The composition of claim 1, wherein the composition also includes an antigen that is selected from the group consisting of peptides, polypeptides, cells, cell extracts, polysaccharides, polysaccharide conjugates, lipids, glycolipids, carbohydrates, viruses, viral extracts and antigens encoded within nucleic acids.
- 9. The composition of claim 8, wherein the antigen is derived from an infectious agent selected from the group consisting of a virus, bacterium, fungus and parasite.
- 10. The composition of claim 8, wherein the antigen is a tumor antigen.
- 11. The composition of claim 8, wherein the antigen is an allergen.

Previous Doc Next Doc Go to Doc#